When Microsoft Corp.'s (NASDAQ: MSFT) first service pack for Windows Vista comes down the chute sometime in 2008, there are indications that massive sales of Vista will happen to those corporate customers who have been "waiting in the wings" for this to upgrade. Historically, bigger corporate citizens wait on deploying new operating systems from Microsoft until the first "service pack" is released. These service packs are generally a huge collection of software "bug" fixes that address many issues that are present when a new piece of software launches.
Even mighty Microsoft is not immune to this rule: "ship when 85% complete, since you'll never ship on time if you need to get to 100%." That's a repeat of a rule I've heard from many software companies, most of which release product when not complete, as was the case with Windows Vista. After all, hitting a shipping deadline is more important than iron-clad products. Standard rule of thumb here.
But will the revenue spigot of Windows Vista sales really see some action once SP1 (service pack 1) is released for Windows Vista next year? From many indications, it will. Support on WindowsXP and Windows 2000 won't last forever, so in effect Microsoft will goad customers into upgrading to Windows Vista (call it standard strong-arm tactics). The release of a 'comforting' initial service pack will ease the security-minded pain of many of these customers, and the non-OEM (original equipment manufacturer), retail sales will finally fall in line to where Microsoft needs them to be.
[Disclosure: I own MSFT shares as of 8-31-07]
Last updated: February 09, 2012: 04:32 PM
Hot Stocks
DailyFinance Headlines
- Why Groupon Will Never Be Great Again
- Why Used Car Bargains Are Getting Harder to Find
- 5 Reasons Facebook Stock May Be a Better Buy Than You Think
- Department Stores Reveal Top Selling Valentine's Gifts
- Readers' Tips for Financial Renewal, Part 4: Get the Right Job
Benzinga Headlines
- How to Profit off Addicts
- The Pepsi Challenge for 8,700 People is to Find a New Job
- How to Profit From Surging Chinese Prices
- Credit Suisse is the Latest Swiss Bank to Disappoint
- Vodafone Misses Quarterly Revenue
TheFlyOnTheWall.com Headlines
- Tesla Motors February put volatility elevated into unveiling of Model X
- Manulife Financial reportedly establishing 'high net worth' unit, DJ says
- Linkedin February weekly 75 straddle priced for 11% move into Q4
- P.A.M. Transportation reports Q4 EPS 2c vs. consensus (12c)
- Tesla Motors teases Model X event on corporate website
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
WalletPop Headlines
- Why Groupon Will Never Be Great Again
- Why Used Car Bargains Are Getting Harder to Find
- 5 Reasons Facebook Stock May Be a Better Buy Than You Think
- Department Stores Reveal Top Selling Valentine's Gifts
- Readers' Tips for Financial Renewal, Part 4: Get the Right Job
My Portfolios
Track your stocks here!
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
BloggingStocks Partners
More from AOL Money & Finance
- Business News
- Stock Screener
- Stock Quotes
- Stock Charts
- Banking
- Identity Theft
- DJIA
- Debt Management
- Loans
- Auto Loan
- Mortgages
- Taxes
- Retirement
- Insurance
- Small Business
- Earnings
- Tech News
- Tax Forms
- Tax Deductions
- Tax Credit
- Tax Audit
- Tax Advice
- Stock Ticker
- Stock Brokers
- Resume Builder
- Pig Flu
- Online Tax Filing
- Madoff
- Investing For Retirement
- Income Tax
- Historical Stock Prices
- GOOG
- ETF Investing
- Deals
- DailyFinance
- Crude Oil Prices
- Credit Score Calculator
- Common Tax Filing Mistakes
- AMT
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
The Money Man Behind Rick Santorum: Who Is Foster S. Friess?
Savings Experiment: Snow Removal

